CTOs on the Move

ParaPRO

www.parapro.com

 
ParaPRO is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.parapro.com
  • 11550 N Meridian St Ste 600
    Carmel, IN USA 46032
  • Phone: 317.428.4597

Executives

Name Title Contact Details

Similar Companies

WESKetch Architecture

WESKetch Architecture is a Millington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

genetic Immunity

genetic Immunity is a Mc Lean, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aktiv Pharma Group

Aktiv Pharma Group is a company that develops drug delivery technology for emergency situations, with a focus on the ARAI auto injector for opioid overdose, hypoglycemia, and severe allergies like anaphylaxis.

Womens International Pharmacy

It is the goal of Women's International Pharmacy, Inc. to provide excellent service and quality compounded prescriptions to our customers. At Women's International Pharmacy, Inc., we are dedicated to providing custom compounded doses of bioidentical

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.